The effect of lowering blood pressure by magnesium supplementation in diabetic hypertensive adults with low serum magnesium levels: a randomized, double-blind, placebo-controlled clinical trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc in the context of low blood pressure and orthostatic hypotension.

To test the blood pressure (BP)-lowering effect of oral magnesium supplementation (that is, magnesium chloride (MgCl(2)) solution) in diabetic hypertensive adults with hypomagnesaemia not on diuretic treatment but receiving concurrent captopril, the researchers conducted a double-blind, placebo-controlled trial.

Why It Was Studied

Eighty-two subjects between 40 and 75 years of age were randomly enrolled.

Who Took Part

The abstract describes 82 subjects taking part.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The subjects were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Blinding on both sides kept the subjects and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

What Was Measured

Topics PubMed links to this paper include Diabetic Angiopathies, Hypertension and Magnesium Chloride.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 82 subjects in people with low blood pressure and orthostatic hypotension.

The publication is from 2009 (Journal of human hypertension), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Low blood pressure and orthostatic hypotension research.